RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of NGM
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

FAQ

What is the symbol for NGM Biopharmaceuticals Inc. Stock and on which exchange is it traded?
The symbol for NGM Biopharmaceuticals Inc. is NGM and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell NGM Biopharmaceuticals Inc. Stock?
NGM Biopharmaceuticals Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy NGM Biopharmaceuticals Inc. Stock?
NGM Biopharmaceuticals Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy NGM Biopharmaceuticals Inc. Stock.

What's the current price of NGM Biopharmaceuticals Inc. Stock?
As of the end of day on the Jul 03, 2024, the price of an NGM Biopharmaceuticals Inc. (NGM) share was $1.54.

What is the 52-week high and low for NGM Biopharmaceuticals Inc. Stock?
The 52-week high for NGM Biopharmaceuticals Inc. Stock is $3.42 and the 52-week low is $0.600.

What is the market capitalization of NGM Biopharmaceuticals Inc. Stock?
As of the Jul 03, 2024, the market capitalization of NGM Biopharmaceuticals Inc. is 128.532M.

When is the next earnings date for NGM Biopharmaceuticals Inc.?
The upcoming earnings date for NGM Biopharmaceuticals Inc. is Aug 01, 2024.
Click to get the best stock tips daily for free!

About NGM Biopharmaceuticals Inc.

NGM Biopharmaceuticals. NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that ac... NGM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT